NCT02030301View on ClinicalTrials.gov

Safety and Efficacy Trial of DNA Vaccines to Treat Genital Herpes in Adults

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

165

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

June 30, 2015

Study Completion Date

February 29, 2016

Conditions
Genital Herpes Simplex Type 2
Interventions
BIOLOGICAL

VCL-HB01

Plasmid DNA vaccine encoding two HSV-2 proteins; formulated with Vaxfectin®

BIOLOGICAL

VCL-HM01

Plasmid DNA vaccine encoding one HSV-2 protein; formulated with Vaxfectin®

BIOLOGICAL

PBS

Phosphate-buffered saline

Trial Locations (7)

33024

Broward Research Group, Hollywood

35294

Alabama Vaccine Research Clinic, Birmingham

46202

Indiana University Infectious Diseases Research, Indianapolis

77004

Center for Clinical Studies, Houston

84132

University of Utah - Division of Infectious Diseases, Salt Lake City

97210

Westover Heights Clinic, Portland

98104

University of Washington Medical Center, Seattle

Sponsors

Lead Sponsor

Vical
All Listed Sponsors
lead

Vical

INDUSTRY

NCT02030301 - Safety and Efficacy Trial of DNA Vaccines to Treat Genital Herpes in Adults | Biotech Hunter | Biotech Hunter